Ebrantil, 5 mg/ml 10 ml 5 pcs

Ebrantil refers to drugs which block post-synaptic alpha-1-adrenoreceptors, due to which peripheral resistance is reduced. In addition, Ebrantil regulates the central mechanism of maintaining vascular tone and has a weak beta-adrenoblocking effect.

The heart rate (HR) and cardiac output do not change with its administration. Low cardiac output may increase due to decreased vascular resistance. As a rule, Ebrantil does not cause orthostatic phenomena. Ebrantil blocks vasoconstriction caused by alpha-2-adrenoreceptors and does not cause reflex tachycardia due to vasodilatation.

Ebrantil reduces systolic and diastolic blood pressure (BP) in a balanced manner by reducing peripheral resistance and does not cause reflex tachycardia.

Urapidil reduces pre- and post-load on the heart and increases the efficiency of the heart contraction, thus, in the absence of arrhythmia, the drug increases the reduced cardiac minute volume.

Indications

Active ingredient

Composition

1 ml. contains urapidyl hydrochloride 5.47 mg (corresponding to 5.0 mg of urapidyl),

Additives:

Propylene glycol;

Sodium hydrophosphate dihydrate;

Sodium dihydrophosphate dihydrate;

water for injection

How to take, the dosage

Ebrantil is administered by intravenous stream or by prolonged infusion – lying down

Hypertensive crisis, severe arterial hypertension, refractory hypertension.

(1) Intravenous: 10-50 mg of Ebrantil is slowly administered intravenously under arterial pressure (BP)/A BP reduction is expected within 5 minutes of administration. Depending on the therapeutic effect, Ebrantil may be administered again.

2) Intravenous drip or continuous infusion using a perfusion pump.

The maintenance dose: an average of 9 mg/h, i.e. 250 mg of Ebrantil (10 ampoules of 5 ml or 5 ampoules of 10 ml) in 500 ml of infusion solution (1 mg = 44 drops ~ 2.2 ml).

The maximum allowable ratio is 4 mg of Ebrantil per 1 ml of the infusion solution.

The recommended maximum initial rate is 2 mg/min,

The drip infusion rate depends on the patient’s BP.

The drip infusion solution for BP maintenance is prepared as follows:

Typically, 250 mg of the drug (10 5 mL ampoules or 5 10 mL ampoules) of Ebrantil is added to 500 mL of an infusion solution, such as physiological solution, 5 or 10% dextrose (glucose) solution. If a perfusion pump is used to administer a maintenance dose, 100 mg of the drug (4 vials of 5 ml or 2 vials of 10 ml) of Ebrantil® is injected into the syringe of the perfusion pump and diluted to 50 ml with physiological solution, 5 or 10% dextrose (glucose) solution.

Interaction

The hypotensive effect of urapidil may increase when co-administered with alpha-adrenoblockers or other hypotensive agents, as well as with hypovolemia (nausea, vomiting) and when taking ethanol.

Concomitant administration of cimetidine may increase the maximum plasma concentration of urapidil by 15%.

Special Instructions

Contraindications

Side effects

Most PEs are caused by a sharp decrease in BP.

Frequency: very frequently, more than 1/10; frequently, more than 1/100 and less than 1/10; infrequently, more than 1/1000 and less than 1/100; rarely, more than 1/10000 and less than 1/1000; very rarely, less than 1/10000, including isolated reports.

Systemic diseases: infrequent – palpitations, tachycardia, bradycardia, feeling of tightness behind the chest, dyspnea, arrhythmias.

Gastrointestinal system disorders: frequently – nausea, infrequently – vomiting.

CNS disorders: frequently – dizziness, headache, fatigue; very rarely – anxiety.

Skin disorders: infrequent – increased sweating.

Allergic reactions: rare – skin itching, redness, exanthema.

Urogenital system: frequently – proteinuria; rarely – nephropathy, nephrotic syndrome; rarely – priapism.

Laboratory indices: very rare – thrombocytopenia.

Overdose

Symptoms: dizziness, orthostatic collapse, fatigue, lethargy.

Treatment: in case of a sharp drop in blood pressure, the patient should be elevated and infusion therapy should be started to increase circulating blood volume. If these measures are ineffective, an infusion of vasoconstrictors may be initiated, with control of blood pressure. In very rare cases, intravenous administration of catecholamines (0.5 – 1.0 mg of epinephrine (adrenaline) diluted in 10 ml of saline solution) is necessary.

Pregnancy use